Interviewee: Eric Lander.
Eric Lander, director of the Whitehead Institute Center for Genome Research, speaks about the private project and the role technology played.
(DNAi Location: Genome > The Project > Players >Technology > Sequencers enabled both projects)
Transcript:
The interesting thing about the Celera announcement was that so much was made about some new strategy. But of course it wasn't about a new strategy, the real heroes of this were the people at Applied Biosystems who developed the new capillary sequencer. The secret of all of this was the availability of a new capillary sequencer, and once it became clear that the new sequencer was going to be available on schedule it was a very simple thing to do, just buy a bunch of those sequencers.
Eric Lander, director of the Whitehead Institute Center for Genome Research, talks about his views on a competing genome project and its effect on funding.
Eric Lander, director of the Whitehead Institute Center for Genome Research, talks about the mistaken notion of the Human Genome Project as "big science."
Craig Venter, leader of the private effort at Celera Genomics, speaks about his company's reliance on the public data for reassembly of the Celera sequence.
Craig Venter, the leader of the private genome effort, talks about the "whole genome shotgun" technique that was used by Celera Genomics to sequence the human genome.